New-onset type 1 diabetes mellitus and anti-aquaporin-4 antibody positive optic neuritis associated with type 1 interferon therapy for chronic hepatitis C

Internal Medicine

Volumn 51, Issue 18, 2012, Pages 2625-2629

  Kawazoe, Tomoya ^a   Araki, Manabu ^a   Lin, Youwei ^a   Ogawa, Masafumi ^a   Okamoto, Tomoko ^a   Yamamura, Takashi ^a   Wakakura, Masato ^b   Murata, Miho ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

^b Inoue Eye Hospital   (Japan)

Author keywords

Aquaporin 4; Chronic hepatitis C; Neuromyelitis optica; Type 1 diabetes mellitus; Type 1 interferon

Indexed keywords

AQUAPORIN 4 ANTIBODY; CYCLOPHOSPHAMIDE; GLYCOSYLATED HEMOGLOBIN; IMMUNOGLOBULIN; INTERFERON; METHYLPREDNISOLONE;

ADULT; ARTICLE; CASE REPORT; DISEASE ASSOCIATION; DRUG MEGADOSE; FEMALE; GLUCOSE BLOOD LEVEL; HEPATITIS C; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; PERIMETRY; PLASMAPHERESIS; VISUAL FIELD DEFECT; VISUALIMPAIRMENT;

ANTIBODIES, ANTI-IDIOTYPIC; ANTIVIRAL AGENTS; AQUAPORIN 4; DIABETES MELLITUS, TYPE 1; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON TYPE I; INTERFERON-ALPHA; INTERFERON-BETA; MIDDLE AGED; OPTIC NEURITIS; RIBAVIRIN;

EID: 84867885398     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.51.7771     Document Type: Article

References (25)

1. Burdick LM, Somani N, Somani AK. Type I IFNs and their role in the development of autoimmune diseases. Expert Opin Drug Saf 8: 459-472, 2009.
2. Cacoub P, Poynard T, Ghillani P, et al. Extrahepatic manifestations of chronic hepatitis C. Arthritis Rheum 42: 2204-2212, 1999.
3. Fabris P, Betterle C, Floreani A, et al. Development of type 1 diabetes mellitus during interferon alfa therapy for chronic HCV hepatitis. Lancet 340: 548, 1992.
4. Okanoue T, Sakamoto S, Itoh Y, et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 25: 283-291, 1996.
5. Manesis EK, Petrou C, Brouzas D, Hadziyannis S. Optic tract neuropathy complicating low-dose interferon treatment. J Hepatol 21: 474-477, 1994.
6. Isler M, Akhan G, Bardak Y, Akkaya A. Dry cough and optic neuritis: two rare complications of interferon alpha treatment in chronic viral hepatitis. Am J Gastroenterol 96: 1303-1304, 2001.
7. Matsuo T, Takabatake R. Multiple sclerosis-like disease secondary to alpha interferon. Ocul Immunol Inflamm 10: 299-304, 2002.
8. Kataoka I, Shinagawa K, Shiro Y, et al. Multiple sclerosis associated with interferon-alpha therapy for chronic myelogenous leukemia. Am J Hematol 70: 149-153, 2002.
9. Hoftberger R, Garzuly F, Dienes HP, et al. Fulminant central nervous system demyelination associated with interferon-alpha therapy and hepatitis C virus infection. Mult Scler 13: 1100-1106, 2007.
10. Kajiyama K, Tsuda K, Takeda M, Yoshikawa H, Tanaka K. Multiple sclerosis with positive anti-aquaporin-4 antibody, manifested after interferon-a-2b/ribavirin therapy for chronic hepatitis C. A case report. Shinkeinaika (Neurol Med) 66: 180-184, 2007 (in Japanese, Abstract in English).
11. Yamasaki M, Matsumoto K, Takahashi Y, Nakanishi H, Kawai Y, Miyamura M. A case of NMO (Neuromyelitis optica) spectrum disorder triggered by interferon alpha, which involved extensively pyramidal tract lesion of the brain. Rinshou Shinkeigaku (Clin Neurol) 52: 19-24, 2012.
12. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364: 2106-2112, 2004.
13. Okuma H, Kawamura Y, Ohnuki Y, Takagi S. Optic neuritis caused by interferon-beta administration. Intern Med 47: 1759, 2008.
14. Shimizu J, Hatanaka Y, Hasegawa M, et al. IFN β -1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum. Neurology 75: 1423-1427, 2010.
15. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 66: 1485-1489, 2006.
16. Matsuoka T, Matsushita T, Kawano Y, et al. Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese. Brain 130: 1206-1223, 2007.
17. Tanaka M, Tanaka K, Komori M. Interferon-beta(1b) treatment in neuromyelitis optica. Eur Neurol 62: 167-170, 2009.
18. Uzawa A, Mori M, Hayakawa S, Masuda S, Kuwabara S. Different responses to interferon beta-1b treatment in patients with neuromyelitis optica and multiple sclerosis. Eur J Neurol 17: 672-676, 2010.
19. Shimizu Y, Fujihara K, Kubo S, et al. Therapeutic efficacy of interferon b-1b in Japanese patients with optic-spinal multiple sclerosis. Tohoku J Exp Med 223: 211-214, 2011.
20. Krumbholz M, Faber H, Steinmeyer F, et al. Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. Brain 131: 1455-1463, 2008.
21. Chihara N, Aranami T, Sato W, et al. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci U S A 108: 3701-3706, 2011.
22. Misu T, Fujihara K, Kakita A, et al. Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain 130: 1224-1234, 2007.
23. Axtell RC, Raman C, Steinman L. Interferon-b exacerbates Th17-mediated inflammatory disease. Trends Immunol 32: 272-277, 2011.
24. Crow MK. Type 1 interferon in organ-targeted autoimmune and inflammatory diseases. Arthritis Res Ther 12(Suppl 1): S5-S14, 2010.
25. Knobler RL, Panitch HS, Braheny SL, et al. Systemic alphainterferon therapy of multiple sclerosis. Neurology 34: 1273-1279, 1984.